The Filing Desk

Codexis vs Harvard Bioscience

Codexis CDXS · Harvard Bioscience HBIO · Life Sciences Tools & Services

Harvard Bioscience reported revenue of $86 million in fiscal 2025, 1.2 times Codexis' $70 million in fiscal 2025. Codexis' revenue grew 18.6% in its latest year, and Harvard Bioscience's fell 8.1%. Codexis had an operating margin of -59.3%, against -56.1% at Harvard Bioscience. Free cash flow was −$24 million at Codexis and $5 million at Harvard Bioscience.

Side by side

CodexisHarvard Bioscience
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$70M$86M
Revenue growth18.6%−8.1%
Revenue growth a year, last 5 years0.4%−3.3%
Gross margin86.7%57.7%
Operating margin−59.3%−56.1%
Net margin−62.5%−65.5%
Free cash flow−$24M$5M
Free cash flow margin−33.9%6.3%
Return on capital−189.5%−56.0%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count18.7%2.0%
Last close$1.05$8.68
P/E at the last close——
Insider trades, last 12 monthssold $933,396bought $202,354, sold $0
Piotroski F-score4 of 93 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CodexisHarvard Bioscience
Operating margin
Percent of revenue
CodexisHarvard Bioscience
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CodexisHarvard Bioscience

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Codexis and Harvard Bioscience pages.